
Throughout February, March And April, All Donations Made To Parasites Without Borders Will Be Matched By PWB And Donated To Floating Doctors
January 23, 2025
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial |
Host-microbe Multiomic Profiling Identifies Distinct COVID-19 Immune Dysregulation in Solid Organ Transplant Recipients |
Real‐world Effectiveness and Safety of Oral Azvudine versus Nirmatrelvir‒ritonavir (Paxlovid) in Hospitalized Patients with COVID-19: A Multicenter, Retrospective, Cohort Study
January 16, 2025
Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis |
Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination versus Influenza Vaccination |
Neurological Post-COVID Syndrome is Associated with Substantial Impairment of Verbal Short-term and Working Memory
January 9, 2025
Mpox Vaccination Hesitancy, Previous Immunization Coverage, and Vaccination Readiness in the African Region | Global Prevalence and Correlates of Mpox Vaccine Acceptance and Uptake |
The Effect of Nirmatrelvir/ritonavir on Short- and Long-term Adverse Outcomes from COVID-19 |
Epidemiological Insights into Chronic Urticaria, Vitiligo, Alopecia Areata, and Herpes Zoster following COVID-19 Infection | Impact of Extended-course Oral Nirmatrelvir/ritonavir in Established Long COVID
January 2, 2025
In-hospital Outcomes of Healthcare-associated Coronavirus Disease 2019 (Omicron) Versus Healthcare-associated Influenza: A Retrospective, Nationwide Cohort Study in Switzerland | Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74, 41 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study from the Czech Republic
December 26, 2024
The Burden of All-Cause Mortality Following Influenza-Associated Hospitalizations | Initial Effectiveness of mRNA-1273 against SARS-CoV-2 Infection | 2024 Update of the RECOVER-Adult Long COVID Research Index | Real-world Effectiveness and Causal Mediation Study of BNT162b2 |
Personality and Neuropsychiatric Symptoms in Individuals Diagnosed with Long COVID | Post-COVID Condition Risk Factors and Symptom Clusters
December 21, 2024
BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age | Post-acute Sequelae of COVID-19 in Cancer Patients: Two Cohorts in UK and Hong Kong
- « Anterior
- 1
- 2
- 3
- 4
- …
- 43
- Siguiente »
Situation Dashboards

World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.